Provided by Tiger Trade Technology Pte. Ltd.

Camp4 Therapeutics Corp.

4.33
-0.1500-3.35%
Volume:33.81K
Turnover:148.99K
Market Cap:271.72M
PE:-1.95
High:4.52
Open:4.46
Low:4.26
Close:4.48
52wk High:7.75
52wk Low:1.41
Shares:62.75M
Float Shares:37.87M
Volume Ratio:0.22
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2250
EPS(LYR):-2.6500
ROE:-545.85%
ROA:-45.25%
PB:-392.09
PE(LYR):-1.63

Loading ...

Major Insider Move at CAMP4 Therapeutics Shakes Up Investor Buzz

TIPRANKS
·
Aug 22

Camp4 Therapeutics Director Andrew J. Schwab Disposes of USD 879,374 in Common Shares

Reuters
·
Aug 22

Canadian GoldCamps Clears Key Regulatory Hurdle With NI 43-101 Report for Mercator Project

TIPRANKS
·
Aug 22

Camp4 Therapeutics CSO Daniel Tardiff Disposes of 1,738 Common Shares Worth $8,272.88

Reuters
·
Aug 20

Canadian GoldCamps to Acquire Majority Stake in Stealthwall West Gold Project in Québec

TIPRANKS
·
Aug 19

Analysts’ Top NA Picks: CAMP4 Therapeutics Corporation (CAMP), Wayfair (W)

TIPRANKS
·
Aug 14

CAMP4 Therapeutics Corp Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Camp4 Therapeutics Q2 EPS $(0.58) Misses $(0.21) Estimate, Sales $1.779M Miss $1.897M Estimate

Benzinga Earnings
·
Aug 14

Camp4 Net Loss Widens to $33.5 Million in Q2 FY26

Reuters
·
Aug 14

CAMP4 Therapeutics Q2 Loss Per Share Misses Estimates on Non-Cash Derivative Charge

Reuters
·
Aug 14

Camp4 Therapeutics Corp Q2 Income from Operations USD -13.38 Million

THOMSON REUTERS
·
Aug 14

Camp4 Therapeutics Corp Q2 EPS USD -0.58 VS. Ibes Estimate USD -0.21

THOMSON REUTERS
·
Aug 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 13

CAMP4 Therapeutics Corp Expected to Post a Loss of 21 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Camp4 Therapeutics CEO Josh Mandel-Brehm Acquires 6,551 Common Shares for $10,809.15

Reuters
·
Aug 06

Camp4 Therapeutics Closes Second Tranche of Private Placement, Raises $50.1 Million

Reuters
·
Aug 04

Camp4 Therapeutics Announces Second Closing of $100 Million Private Placement

THOMSON REUTERS
·
Aug 04

CAMP4 Wins Australia Clearance to Start Phase 1/2 Trial of Cmp-002 in Syngap1 Disorder

Reuters
·
Jul 29

Analysts Offer Insights on NA Companies: CAMP4 Therapeutics Corporation (CAMP), Fiserv (FISV) and Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Jul 28

Camp4 Wins Australian Clearance for Phase 1/2 Cmp-002 Trial in SYNGAP1-related Disorder

Reuters
·
Jul 27